Association between serum aluminum levels and cardiothoracic ratio in patients on chronic hemodialysis

Tzu-Lin Wang¹, Yu-Wei Fang²,3, Jyh-Gang Leu²,3, Ming-Hsien Tsai²,3,4*

¹ Division of Cardiology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C., ² Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C., ³ Fu-Jen Catholic University School of Medicine, Taipei, Taiwan, R.O.C., ⁴ Division of Biostatistics, Institutes of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, R.O.C.

* chaosmyth.tw@gmail.com

Abstract

The cardiothoracic ratio (CTR) and serum aluminum levels are both associated with mortality in hemodialysis patients. However, limited data regarding the association between serum aluminum levels and the CTR have been published to date. Therefore, we aimed to elucidate this association in patients on chronic hemodialysis (CHD). We investigated the association between the serum aluminum level and the CTR in CHD in a retrospective cross-sectional study of 547 Taiwanese patients on CHD. The mean age of patients was 62.5 ±13.2 years, with a mean hemodialysis time of 7.1±5.2 years. Among the patients, 36.9% were diabetic and 47.9% were male. After natural logarithmic transformation (ln(aluminum)), the serum aluminum level exhibited an independent and linear relationship with the CTR (β: 1.40, 95% confidence interval (CI), 0.6–2.2). A high serum aluminum level (>6 ng/dL) was significantly associated with a CTR >0.5 in the crude analysis (odds ratio (OR): 2.15, 95% CI, 1.52–3.04) and remained significant after multivariable adjustment (OR: 2.45, 95% CI, 1.63–3.67). Moreover, the ln(aluminum) value was significantly associated with a CTR >0.5 (OR: 1.71, 95% CI, 1.28–2.29) in multivariable analysis, indicating a dose effect of aluminum on cardiomegaly. In conclusion, the serum aluminum level was independently associated with cardiac remodeling (elevated CTR) in patients on CHD.

Introduction

The cardiothoracic ratio (CTR) is estimated by measuring the proportion of the heart size to the thoracic diameter on chest radiographs and it has been shown weakly and negatively associated with cardiac systolic dysfunction [1, 2]. Moreover, a CTR >50% is considered cardiomegaly, and an increased CTR will lead to a poor clinical prognosis in the elderly [3], patients with heart failure [4–6], hypertension [7] and chronic dialysis [8–14]. Ventricular remodeling refers to changes in the size, shape, structure, and function of the heart [15]. Therefore, the
CTR could be representative of the ventricular remodeling status and is a simple method to assess the heart conditions of patients on chronic dialysis.

An elevated aluminum level contributes to the development of dialysis dementia, adynamic bone disease, and anemia in patients on chronic hemodialysis (CHD) [16–18]. Currently, overt aluminum toxicity is uncommon in patients on CHD [19, 20] because the aluminum in the water used for dialysis is removed by reverse osmosis and deionization. However, serum aluminum remains an important issue for patients on CHD due to inefficient removal of aluminum by dialysis and more frequent exposure to aluminum-containing medications [21, 22]. Some studies have reported that elevated serum aluminum levels are associated with mortality in patients on CHD [23, 24]. Moreover, aluminum might have a damaging effect on cardiac remodeling, as evidenced by studies showing a significant association between heart damage and aluminum levels [25, 26].

However, no study has examined the association between the CTR and serum aluminum level in dialysis patients. Therefore, we conducted the present study to investigate their association in patients on CHD.

Materials and methods

Study design and patients

We conducted a retrospective cross-sectional study in a single medical center of Shin-Kong Wu Ho-Su Memorial Hospital. The inclusion criteria were that patients had undergone regular hemodialysis for at least three months before being enrolled in the study and must have been clinically stable for three months preceding the study, without hospitalization for any reason. Moreover, patients without serum aluminum level and CTR data were excluded. Thereafter, a total of 547 patients receiving regular hemodialysis in the dialysis unit of the Shin Kong Wu Ho-Su Memorial Hospital were included in the study from December 2009 to December 2012. Just first dataset of every patient was put into analysis. This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Shin-Kong Wu Ho-Su Memorial Hospital. Moreover, informed consent was waived by the Ethics Committee of the Shin-Kong Wu Ho-Su Memorial Hospital because our study was based on a medical chart review. Patient information was anonymized and de-identified prior to analysis.

Medical and laboratory data

We obtained the data from patients’ medical records, including demographic data and comorbidity and dialysis-related biochemistry results. The information included age, gender, smoking history (never versus ever), blood pressure, which was recorded as the mean value of two measurements before the last dialysis session of a week, history of diabetes mellitus (DM), cardiovascular disease (CVD) diagnosed according to a documented history of coronary artery or cerebrovascular disease, body mass index, HD vintage, CTR, serum aluminum and albumin levels, total cholesterol, triglyceride, iron profile, hemoglobin levels, intact parathyroid hormone (iPTH), ionized calcium, phosphate levels, and urea kinetics (Kt/V). Blood samples were collected for laboratory testing after at least 8 h of fasting and before the dialysis session. Biochemical measurements were performed with standard commercial assays and automated testing instruments (Beckman, Lane Cove, NSW, Australia). iPTH was measured using the Roche Elecsys assay (Roche Diagnostics, Basel, Switzerland). Additionally, aluminum was measured by graphite furnace atomic absorption spectrometry using a GBC 906AA (Braeside VIC, Australia).
Cardiothoracic ratio measurement

Posterior-anterior chest radiographs were obtained to regularly measure the CTR at the end of the year for patients on CHD after a mid-week HD session at our medical center. We used computer software (UniWeb Viewer, EBM Technologies Inc., Taiwan) to ensure the accuracy of measurements. The CTR was calculated by dividing the maximal horizontal width of the heart by the horizontal diameter of inner borders of the rib cage. Therefore, a CTR >0.5 was defined as cardiomegaly, with higher CTR levels indicating a greater severity of cardiomegaly.

Statistical analyses

Data are expressed as the mean ± standard deviation (SD) or median with interquartile range (25th–75th percentile, IQR) as appropriate for continuous variables and as proportions for categorical data. A natural log transformation (ln) was used to approximate a normal distribution if the variable did not have a normal distribution. The Pearson correlation coefficient was adopted to examine the correlations between variables. Linear regression analyses were performed using the CTR as the dependent variable to investigate its association with the ln(aluminum) value. Moreover, a generalized linear model was used to determine the risk of a CTR >0.5 using the link function of logit. Subgroup analysis was also performed and was stratified by the factors of gender (male and female), age (≤60 and >60 years), previous CVD (yes and no), DM (yes and no), and hemoglobin level (≤9 and >9 g/dL) separately. A two-tailed P-value of <0.05 was considered statistically significant. All statistical analyses were performed using SAS for Windows version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results

The mean age of the 547 patients on CHD was 62.5±13.2 years, with a mean HD time of 7.1±5.2 years. Among them, 36.9% were diabetic and 47.9% were male. Two hundred fifty-four (46.4%) patients had a CTR >0.5, and 55 (10%) patients had a CTR >0.6. The mean CTR was 50.4±7.1% (IQR, 46–56%). Moreover, two hundred twenty-eight (41.6%) patients had an aluminum level ≥6 ng/mL and 22 (4%) patients had the level more than 20 ng/mL. The other clinical characteristics of the participants are shown in Table 1. The median serum aluminum level was 5.3 (IQR, 3.5–8.6) ng/mL with a distribution skewed toward the right (Fig 1). Moreover, the significant linear association between ln(aluminum) values and the CTR is shown in Fig 2. The CTR distribution was stratified based on a serum aluminum level of 6 ng/mL, and the group with an aluminum level ≥6 ng/mL had a greater mean CTR (Fig 3).

Determinants of the CTR in patients on CHD

Table 2 shows that age, gender, previous CVD, smoking, diastolic BP, ln(aluminum), albumin, hemoglobin, transferrin saturation, ionized calcium, and phosphate were significantly associated with the CTR in the crude analysis. However, after adjusting for multiple variables, only age, body mass index, ln(aluminum), hemoglobin, and transferrin saturation were significantly associated with the CTR.

Association between serum aluminum levels and the CTR

In further stepwise modeling and analysis (Table 3), a higher serum aluminum level (≥6 ng/mL) was significantly associated with a CTR >0.5 (odds ratio [OR], 2.15; 95% confidence interval [CI], 1.52–3.04) in the crude analysis. After further adjustment to demographic variables and comorbidity and dialysis-related parameters, significance was maintained with an OR of 2.45 (95% CI 1.63–3.67). Moreover, the ln(aluminum) value was also significantly
associated with a CTR >0.5 (OR, 1.67; 95% CI, 1.30–2.14) in the crude analysis. After further adjustment for confounding variables, significance was maintained with an OR of 1.71 (95% CI 1.28–2.29).

Subgroup analysis

We investigated the association between the bivariate aluminum level (with a cutoff value of 6 ng/mL) and a CTR >0.5 in analyses stratified by covariates including a history of DM, previous CVD, hemoglobin, age, and gender. Fig 4 shows that a higher aluminum level (≥6 ng/dL) was significantly associated with a CTR >0.5 in the group without CVD and the group with a hemoglobin value >9 g/dL after multivariable adjustment for demographic characteristics and laboratory data regarding HD. The serum aluminum level seems to have no discrepant effect in groups with different genders, ages or DM histories.

Discussion

In this cross-sectional study of 547 patients on CHD, both higher serum aluminum (≥6 ng/mL) and ln(aluminum) levels were independently correlated with a CTR >0.5. Moreover, a linear association was also noted between ln(aluminum) and continuous CTR values. These
relationships were independent of traditional anemia risk factors. This finding emphasizes that aluminum may have a toxic effect on cardiac remodeling in patients on CHD and may serve as an initiator of cardiomegaly. Physicians should maintain serum aluminum levels as low as possible in dialysis patients.

The echocardiography is the optimal method for determination of cardiomegaly and especially left ventricular function because CTR can be increased due to epicardial fat pad, expiration, and fluid overload [27, 28]. However, an autopsy study has reported a satisfactory association between CTR and heart size [29]. Moreover, some studies have disclosed that CTR had significant association with CV mortality [9, 12, 14] or CV events [11, 13] in patients on CHD. Thereafter, an elevated CTR may indicate heart problem in certain extent and then it allows us to use CTR as the surrogate of ventricular remodeling in patients on CHD because CTR is a simple and inexpensive method.

We proposed a hypothesis regarding our finding that the serum aluminum level is independently and significantly associated with cardiomegaly (CTR >0.5) in patients on CHD. A previous in vitro study indicated that aluminum inhibits the regeneration of reduced glutathione, thereby leading to oxidative damage [30]. Oxidative stress induced by aluminum will cause a disturbance of the intracellular redox system and will consequently contribute to cardiomyopathy and atherosclerosis [31], which could partially explain the poor clinical outcomes in

![Distribution of serum aluminum levels in patients on chronic hemodialysis.](https://doi.org/10.1371/journal.pone.0190008.g001)

Mean: 7.15  
Standard deviation: 6.12  
Median: 5.3  
Interquartile range: 3.5-8.6
patients on CHD. However, the actual mechanism still requires further exploration. Moreover, in our subgroup analysis, a higher serum aluminum level was not significantly associated with cardiomegaly in groups with hemoglobin levels ≤9 g/dL or CVD history. This may have occurred because anemia and CVD are both strong risk factors for the development of cardiomegaly in patients on CHD [32, 33] and may negate the impact of the hazardous effect of aluminum on the heart.

The National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (KDOQI) guideline [34] recommends that physicians should take actions to decrease the serum aluminum level in patients on CHD when it exceeds 20 ng/mL. However, according to our study, we suggest that an early alert is needed, even when the aluminum level is only slightly above the normal range (0–6 ng/mL) due to its hazardous effect on cardiac remodeling. Clinically, dialysis patients have a higher chance of being exposed to aluminum-containing products, including aluminum-containing phosphate binders and antacids, iron and calcium-containing...
A

N: 319
Mean: 49.4
Standard deviation: 7.1

B

N: 228
Mean: 51.8
Standard deviation: 7.0
medications, calcitriol, vitamin B complex, erythropoietin, and insulin [21, 35–37]. Aluminum-containing phosphate binders are one of the most common sources of aluminum [38], and the KDOQI has suggested discontinuing their use. However, aluminum-containing phosphate binders are still being used in some countries due to financial reasons or uncontrolled

![Fig 3. Distribution of the cardiothoracic ratio (%) in groups of patients on chronic hemodialysis with serum aluminum levels (a)<6 ng/mL and (b) ≥6 ng/mL.](https://doi.org/10.1371/journal.pone.0190008.g003)

### Table 2. Determinants of the cardiothoracic ratio.

| Parameter                        | Crude |          |            | Multivariable |          |
|----------------------------------|-------|----------|------------|--------------|----------|
|                                  | β (95% CI) | P       | β (95% CI) | P       |
| Age (per year)                   | 0.18 (0.14, 0.23) | <0.001 | 0.18 (0.13, 0.23) | <0.001 |
| Male versus female               | -2.53 (-3.72, -1.35) | <0.001 | -0.51 (-1.81, 0.78) | 0.435 |
| Duration of dialysis (per year)  | 0.07 (-0.04, 0.19) | 0.198 | 0.11 (-0.004, 0.23) | 0.059 |
| Diabetes mellitus (yes vs no)    | 1.22 (-0.02, 2.46) | 0.054 | 1.24 (-0.04, 2.53) | 0.058 |
| Previous CVD (yes vs no)         | 2.22 (0.83, 3.60) | 0.002 | 0.69 (-0.61, 1.99) | 0.298 |
| Smoking (ever versus never)      | -2.37 (-3.87, -0.87) | 0.002 | -1.33 (-2.83, 0.16) | 0.082 |
| Systolic BP (per 10 mmHg)        | -0.01 (-0.18, 0.16) | 0.887 | 0.17 (-0.08, 0.43) | 0.185 |
| Diastolic BP (per 10 mmHg)       | -0.38 (-0.72, -0.04) | 0.031 | 0.12 (-0.43, 0.68) | 0.661 |
| Body mass index (per 1 kg/m²)    | 0.09 (-0.05, 0.24) | 0.207 | 0.17 (0.03, 0.31) | 0.017 |
| ln(aluminum) (per 1 unit)        | 1.78 (0.95, 2.61) | <0.001 | 1.40 (0.60, 2.20) | 0.001 |
| Albumin level (per 1 g/dL)       | -3.29 (-4.79, -1.79) | <0.001 | 0.10 (-1.50, 1.70) | 0.900 |
| ln(Triglyceride) (per 1 unit)    | -0.50 (-1.48, 0.46) | 0.307 |              |          |
| Cholesterol level (per 1 mg/dL)  | 0.001 (-0.01, 0.01) | 0.962 |              |          |
| Kt/V (per 1 unit)                | 1.08 (-1.25, 3.43) | 0.363 |              |          |
| Hemoglobin (per 1 g/dL)          | 0.98 (-1.41, -0.54) | <0.001 | 0.65 (-1.09, -0.22) | 0.003 |
| ln(iPTH) (per 1 unit)            | 0.26 (-0.29, 0.82) | 0.357 |              |          |
| Transferrin saturation (per 1%)  | 0.09 (-0.13, -0.04) | <0.001 | 0.07 (-0.11, -0.03) | <0.001 |
| Ionized calcium (per 1 mg/dL)    | 1.74 (0.53, 2.95) | 0.005 | 0.93 (-0.22, 2.08) | 0.113 |
| Phosphate (per 1 mg/dL)          | -0.48 (-0.92, -0.05) | 0.029 | -0.14 (-0.55, 0.26) | 0.480 |

Abbreviation: aOR, adjusted odds ratio; CVD, cardiovascular disease; BP, blood pressure; Kt/V, urea kinetics; iPTH, intact parathyroid hormone

### Table 3. Logistic regression analysis of risk factors for cardiomegaly (CTR>0.5) in patients on chronic hemodialysis.

| Parameter                        | Aluminum cut-off value of 6 ng/mL | Each increment of ln(aluminum) |
|----------------------------------|----------------------------------|--------------------------------|
|                                  | OR (95% CI) | P value | OR (95% CI) | P value |
| Crude                            | 2.15 (1.52–3.04) | <0.001 | 1.67 (1.30–2.14) | <0.001 |
| Model 1                          | 2.36 (1.62–3.45) | <0.001 | 1.73 (1.32–2.27) | <0.001 |
| Model 2                          | 2.21 (1.50–3.26) | <0.001 | 1.69 (1.28–2.24) | <0.001 |
| Model 3                          | 2.45 (1.63–3.67) | <0.001 | 1.71 (1.28–2.29) | <0.001 |

Multivariate model 1 is adjusted for age, gender, and hemodialysis vintage. Multivariate model 2 comprises model 1 as well as adjustments for diabetes mellitus, cardiovascular disease, smoking, systolic blood pressure, diastolic blood pressure and body mass index. Multivariate model 3 comprises model 2 as well as adjustments for albumin, hemoglobin, transferrin saturation, ionized calcium, and phosphate.

Abbreviation: OR, odds ratio; CI, confidence interval; ln, natural log transformation

[https://doi.org/10.1371/journal.pone.0190008.t003](https://doi.org/10.1371/journal.pone.0190008.t003)
Hyperphosphatemia [39]. Therefore, more intensive screening of the serum aluminum level is needed for such patients, and an early response is necessary if the serum aluminum level is beyond the normal range.

Our study had some limitations that should be considered when elaborating the results. First, due to the cross-sectional design, the causal relationship between serum aluminum levels and CTRs cannot be inferred. However, according to previous studies [25, 26] and based on the pathological view, we suggest that an elevated serum aluminum level occurs before cardiomegaly. Second, this was a single-center study, and the results might not be applicable to all CHD populations. Generalization of the results should be clarified in further studies. However, the strong association between the serum aluminum level and CTR > 0.5 in our study may extenuate this limitation. Third, some patients might not follow the guideline to take the picture of chest X-ray, which would introduce an overestimate of CTR due to fluid overload. However, this occurred at a random pattern and then the inferred result would not be altered because this bias contributed equally to the groups. Finally, we did not assess the internal variability of the CTR measurement. However, the use of computer-assisted CTR measurements may diminish this bias because this method has been shown to be a simple and reliable method to assess the heart [40].

**Conclusion**

A significant and independent association was observed between higher serum aluminum levels (higher than the normal range) and cardiomegaly (CTR > 0.5) in patients on CHD. Therefore, exposure to aluminum-containing medication should be avoided as much as possible to impede the elevation of serum aluminum levels in patients on CHD.
Supporting information

S1 Dataset. The collected data in the study. (XLSX)

Acknowledgments
We thank our patients for contributing the dataset to this study.

Author Contributions
Conceptualization: Yu-Wei Fang.
Data curation: Tzu-Lin Wang, Ming-Hsien Tsai.
Formal analysis: Ming-Hsien Tsai.
Investigation: Ming-Hsien Tsai.
Methodology: Jyh-Gang Leu, Ming-Hsien Tsai.
Supervision: Ming-Hsien Tsai.
Validation: Tzu-Lin Wang, Yu-Wei Fang, Ming-Hsien Tsai.
Writing – original draft: Tzu-Lin Wang.
Writing – review & editing: Yu-Wei Fang, Jyh-Gang Leu, Ming-Hsien Tsai.

References
1. Philbin EF, Garg R, Danisa K, Denny M, Gosselin G, Hassapoyannes C, et al. The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. Digitalis Investigation Group. Arch Intern Med. 1998; 158(5):501–6. PMID: 9508228
2. Hammermeister KE, Chikos PM, Fisher L, Dodge HT. Relationship of cardiothoracic ratio and plain film heart volume to late survival. Circulation. 1979; 59(1):89–95. PMID: 758128
3. Frishman WH, Nadelmann J, Ooi WL, Greenberg S, Heiman M, Kahn S, et al. Cardiomegaly on chest x-ray: prognostic implications from a ten-year cohort study of elderly subjects: a report from the Bronx Longitudinal Aging Study. Am Heart J. 1992; 124(4):1026–30. PMID: 1388323
4. Kearney MT, Fox KA, Lee AJ, Brooksby WP, Shah AM, Flapan A, et al. Predicting sudden death in patients with mild to moderate chronic heart failure. Heart. 2004; 90(10):1137–43. https://doi.org/10.1136/hrt.2003.021733 PMID: 15367507
5. Giamouzis G, Sui X, Love TE, Butler J, Young JB, Ahmed A. A propensity-matched study of the association of cardiothoracic ratio with morbidity and mortality in chronic heart failure. Am J Cardiol. 2008; 101(3):343–7. https://doi.org/10.1016/j.amjcard.2007.08.039 PMID: 18237597
6. Dimopoulos K, Giannakoulas G, Bendayan I, Liodakis E, Petracco R, Diller GP, et al. Cardiothoracic ratio from postero-anterior chest radiographs: a simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease. Int J Cardiol. 2013; 166(2):453–7. https://doi.org/10.1016/j.ijcard.2011.10.125 PMID: 22137450
7. Rayner BL, Goodman H, Opie LH. The chest radiograph. A useful investigation in the evaluation of hypertensive patients. Am J Hypertens. 2004; 17(6):507–10. https://doi.org/10.1016/j.amjhyper.2004.02.012 PMID: 15117523
8. Yen TH, Lin JL, Lin-Tan DT, Hsu KH. Cardiothoracic ratio, inflammation, malnutrition, and mortality in diabetes patients on maintenance hemodialysis. Am J Med Sci. 2009; 337(6):421–8. https://doi.org/10.1097/MAJ.0b013e31819bbee1 PMID: 19525660
9. Chen KH, Lin-Tan DT, Huang WH, Hung CC, Chang CT, Huang JY, et al. Cardiothoracic ratio, malnutrition, inflammation, and two-year mortality in non-diabetic patients on maintenance hemodialysis. Kidney Blood Press Res. 2008; 31(3):143–51. https://doi.org/10.1159/000127388 PMID: 18424899
10. Chen KH, Hung CC, Lin-Tan DT, Huang WH, Hsu CW, Weng SM, et al. Cardiothoracic ratio association with mortality in patients on maintenance peritoneal dialysis. Ther Apher Dial. 2011; 15(1):81–8. https://doi.org/10.1111/j.1744-9987.2010.00860.x PMID: 21272257
11. Yotsueda R, Taniguchi M, Tanaka S, Eriguchi M, Fujisaki K, Torisu K, et al. Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study. Am J Kidney Dis. 2017; 70(1):84–92. https://doi.org/10.1053/j.ajkd.2016.11.026 PMID: 28196648

12. Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, et al. The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. Clin Exp Nephrol. 2017; 21(5):797–806. https://doi.org/10.1007/s10157-017-1380-2 PMID: 28508128

13. Okute Y, Shoji T, Hayashi T, Kuwamura Y, Sonoda M, Mori K, et al. Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients. J Atheroscler Thromb. 2017; 24(4):412–21. https://doi.org/10.5551/jat.36426 PMID: 27629255

14. Tsai MH, Liou HH, Leu JG, Yen MF, Chen HH. Sites of peripheral artery occlusive disease as a predictor for all-cause and cardiovascular mortality in chronic hemodialysis. PLoS One. 2015; 10(6):e0128968. https://doi.org/10.1371/journal.pone.0128968 PMID: 26035831

15. Mihi C, Dassen WR, Kuipers H. Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes. Neth Heart J. 2008; 16(4):129–33. PMID: 18427637

16. Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc. 2006; 7(9 Suppl):S7–S12; quiz S7-21. https://doi.org/10.1016/j.jamda.2006.09.005 PMID: 17098634

17. Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986; 1(5):391–8. https://doi.org/10.1002/jbmr.565010503 PMID: 3503554

18. Rob PM, Niederstadt C, Reusche E. Dementia in patients undergoing long-term dialysis: aetiology, differential diagnoses, epidemiology and management. CNS Drugs. 2001; 15(9):691–9. PMID: 11580308

19. Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Arch Intern Med. 1991; 151(2):319–22. PMID: 19929591

20. Gault PM, Allen KR, Newton KE. Plasma aluminium: a redundant test for patients on dialysis? Ann Clin Biochem. 2005; 42(Pt 1):51–4. https://doi.org/10.1258/0004563053026862 PMID: 15802033

21. Bohrer D, Bertagnolli DC, de Oliveira SM, do Nascimento PC, de Carvalho LM, Pomblum SG. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant. 2007; 22(2):605–11. https://doi.org/10.1093/ndt/gfl569 PMID: 17035374

22. Gura KM. Aluminum contamination in products used in parenteral nutrition: has anything changed? Nutrition. 2010; 26(6):585–94. https://doi.org/10.1016/j.nut.2009.10.015 PMID: 20363591

23. Chazan JA, Lew NL, Lowrie EG. Increased serum aluminum. An independent risk factor for mortality in patients undergoing long-term hemodialysis. Arch Intern Med. 1991; 151(2):319–22. PMID: 19929591

24. Adamek S, Libansky P, Lischke R, Foltan R, Kubinyi J, Broulik P. [Surgical therapy of primary hyperparathyroidism in strength and endurance athletes. Neth Heart J. 2008; 16(4):129–33. PMID: 18427637

25. Clark AL, Coats AJ. Unreliability of cardiothoracic ratio as a marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography. Postgrad Med J. 2000; 76(895):289–91. https://doi.org/10.1136/jpmj.76.895.289 PMID: 10775282

26. Neophytou AM, Noth EM, Liu S, Costello S, Hammond SK, Cullen MR, et al. Ischemic Heart Disease Incidence in Relation to Fine versus Total Particulate Matter Exposure in a U.S. Aluminum Industry Cohort. PLoS One. 2016; 11(6):e0156613. https://doi.org/10.1371/journal.pone.0156613 PMID: 27249060

27. Clark AL, Coats AJ. Unreliability of cardiothoracic ratio as a marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography. Postgrad Med J. 2000; 76(895):289–91. https://doi.org/10.1136/jpmj.76.895.289 PMID: 10775282

28. Kono T, Suwa M, Hanada H, Hirota Y, Kawamura K. Clinical significance of normal cardiac silhouette in dilated cardiomyopathy—evaluation based upon echocardiography and magnetic resonance imaging. Jpn Circ J. 1992; 56(4):359–65. PMID: 1578607

29. Murphy ML, Blue LR, Thenabadu PN, Phillips JR, Ferris EJ. The reliability of the routine chest roentgenogram for determination of heart size based on specific ventricular chamber analysis at postmortem. Invest Radiol. 1985; 20(1):21–5. PMID: 3156821

30. Murakami K, Yoshino M. Aluminum decreases the glutathione regeneration by the inhibition of NADP-isocitrate dehydrogenase in mitochondria. J Cell Biochem. 2004; 93(6):1267–71. https://doi.org/10.1002/jcb.20261 PMID: 15486972
31. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int. 2005; 9(1):37–46. https://doi.org/10.1111/j.1492-7535.2005.01116.x PMID: 16191052

32. Liou KY, Liou HH, Fang YW, Leu JG, Tsai MH. Association between peripheral arterial occlusive disease and cardiothoracic ratio in patients on chronic hemodialysis. Sci Rep. 2016; 6:38458. https://doi.org/10.1038/srep38458 PMID: 27918569

33. Asakawa T, Joki N, Tanaka Y, Hayashi T, Hase H, Komatsu Y, et al. Association between the Hemoglobin Level and Cardiothoracic Ratio in Patients on Incident Dialysis. Cardiorenal Med. 2014; 4(3–4):189–200. https://doi.org/10.1159/000368200 PMID: 25737683

34. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1–201.

35. Reinke CM, Breitkreutz J, Leuenberger H. Aluminium in over-the-counter drugs: risks outweigh benefits? Drug Saf. 2003; 26(14):1011–25. PMID: 14583063

36. Gura KM. Aluminum contamination in parenteral products. Curr Opin Clin Nutr Metab Care. 2014; 17(6):551–7. https://doi.org/10.1097/MCO.0000000000000091 PMID: 25023185

37. Bohrer D, Bertagnolli DC, de Oliveira SM, do Nascimento PC, de Carvalho LM, Garcia SC, et al. Role of medication in the level of aluminium in the blood of chronic haemodialysis patients. Nephrol Dial Transplant. 2009; 24(4):1277–81. https://doi.org/10.1093/ndt/gfn631 PMID: 19028749

38. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med. 1991; 324(8):527–31. https://doi.org/10.1056/NEJM199102213240804 PMID: 1992306

39. Bikbov B, Bieber B, Andrusov A, Tomilina N, Zemchenkov A, Zhao J, et al. Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons. Hemodial Int. 2017; 21(3):393–408. https://doi.org/10.1111/hdi.12503 PMID: 27790813

40. Nakamori N, Doi K, MacMahon H, Sasaki Y, Montner S. Effect of heart-size parameters computed from digital chest radiographs on detection of cardiomegaly. Potential usefulness for computer-aided diagnosis. Invest Radiol. 1991; 26(6):546–50. PMID: 1830564